The global nuclear medicine market, valued at $5.2 billion in 2022, is projected to grow to $11.4 billion by 2031, with a compound annual growth rate (CAGR) of 9.2% from 2023 to 2031, according to Transparency Market Research. This growth is driven by the rising prevalence of chronic diseases, advancements in imaging technologies such as PET and SPECT, and an increased focus on personalized medicine. North America is leading the market, supported by significant investments in healthcare infrastructure and research. Recently, Smilow Cancer Hospital in Connecticut has upgraded its radiotherapy treatment plan using RefleXion Medical's X1 platform to enhance patient treatment for metastatic cancer.
Mon, 23 Sep 2024 11:18:15 GMT | GlobeNewswire